Concert Pharmaceuticals Inc. (CNCE)

6.95
NASDAQ : Health Technology
Prev Close 6.81
Day Low/High 6.80 / 7.14
52 Wk Low/High 5.36 / 17.83
Avg Volume 226.30K
Exchange NASDAQ
Shares Outstanding 23.84M
Market Cap 162.36M
EPS -2.40
P/E Ratio N/A
Div & Yield N.A. (N.A)
Concert Pharmaceuticals Names Thomas Auchincloss To Board Of Directors And Chair Of The Audit Committee

Concert Pharmaceuticals Names Thomas Auchincloss To Board Of Directors And Chair Of The Audit Committee

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced today that Thomas G.

Jazz Pharmaceuticals And Concert Pharmaceuticals Provide JZP-386 Program Update

Jazz Pharmaceuticals And Concert Pharmaceuticals Provide JZP-386 Program Update

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Reports Third Quarter 2014 Financial Results And Provides Update On CTP-354 Program

Concert Pharmaceuticals Reports Third Quarter 2014 Financial Results And Provides Update On CTP-354 Program

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2014 and provided an update on its pipeline and CTP-354.

Concert Pharmaceuticals To Present At Stifel 2014 Healthcare Conference On November 18, 2014

Concert Pharmaceuticals To Present At Stifel 2014 Healthcare Conference On November 18, 2014

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the Stifel 2014 Healthcare Conference, November 18, 2014 at 1:50 p.

Concert Pharmaceuticals To Report Third Quarter 2014 Results On November 12, 2014

Concert Pharmaceuticals To Report Third Quarter 2014 Results On November 12, 2014

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its third quarter 2014 financial results on Wednesday, November 12, 2014 before the financial markets open.

Concert Pharmaceuticals Presents Positive Data From Multiple Dose Phase 1 Clinical Trial Of CTP-354, Lead Candidate For The Treatment Of Spasticity

Concert Pharmaceuticals Presents Positive Data From Multiple Dose Phase 1 Clinical Trial Of CTP-354, Lead Candidate For The Treatment Of Spasticity

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced today Phase 1 data of CTP-354, a novel, potentially first-in-class, non-sedating, once-daily oral treatment for spasticity.

Concert Pharmaceuticals Announces Initiation Of CTP-730 Phase 1 Clinical Trial Under Celgene Collaboration

Concert Pharmaceuticals Announces Initiation Of CTP-730 Phase 1 Clinical Trial Under Celgene Collaboration

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated a Phase 1 clinical trial of CTP-730, a novel product candidate that is being developed under its strategic collaboration with...

4 Under-$10 Biotech Stocks in Breakout Territory

4 Under-$10 Biotech Stocks in Breakout Territory

These biotech stocks trading for less than $10 a share are within range of triggering breakout trades.

Concert Pharmaceuticals Achieves $2 Million Milestone For AVP-786 Under Avanir Pharmaceuticals Collaboration

Concert Pharmaceuticals Achieves $2 Million Milestone For AVP-786 Under Avanir Pharmaceuticals Collaboration

Concert Pharmaceuticals, Inc. (NASDQ: CNCE) today announced that it has achieved a $2 million milestone under its development and license agreement with Avanir Pharmaceuticals, Inc.

Concert Pharmaceuticals To Present At Robert W. Baird 2014 Healthcare Conference On September 4, 2014

Concert Pharmaceuticals To Present At Robert W. Baird 2014 Healthcare Conference On September 4, 2014

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present an overview at the Robert W.

4 Stocks Under $10 Making Big Moves

4 Stocks Under $10 Making Big Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Concert Pharmaceuticals Reports Second Quarter 2014 Financial Results And Provides Company Update

Concert Pharmaceuticals Reports Second Quarter 2014 Financial Results And Provides Company Update

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2014.

Concert Pharmaceuticals To Report Second Quarter 2014 Results On August 12, 2014

Concert Pharmaceuticals To Report Second Quarter 2014 Results On August 12, 2014

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its second quarter 2014 financial results on Tuesday, August 12, 2014 before the financial markets open.

Http://www.jazzpharmaceuticals.com/

Http://www.jazzpharmaceuticals.com/

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Announces FDA Lifts Partial Clinical Hold For CTP-354, A Novel Drug Candidate For Spasticity

Concert Pharmaceuticals Announces FDA Lifts Partial Clinical Hold For CTP-354, A Novel Drug Candidate For Spasticity

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the FDA has provided notification that the Company has completed the necessary preclinical toxicology testing in order to administer repeated doses of...

Concert Pharmaceuticals Announces Successful End-of-Phase 2 Meeting With FDA For CTP-499

Concert Pharmaceuticals Announces Successful End-of-Phase 2 Meeting With FDA For CTP-499

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced the successful completion of an End-of-Phase 2 meeting with the U.

Top Insider Trades: ARP CNCE FSFR APL

Top Insider Trades: ARP CNCE FSFR APL

The top 10 open-market insider purchases and sales filed at the SEC Thursday.

Looking for Follow-Through

Wednesday's failure suggests a probe to 50% of the October-to-December range at 860 to 861 S&P.

Conseco Seeks Chapter 11 Protection

Conseco Seeks Chapter 11 Protection

The consumer finance giant becomes the third biggest U.S. bankruptcy proceeding.

Sometimes, You Have to Accentuate the Negative

New revelations about Tyco, Computer Associates, Conseco remind us to think critically.

Teetering Conseco Posts a Huge Loss

Teetering Conseco Posts a Huge Loss

The debt-heavy insurer and lender is one step closer to the grave after a $1.77 billion loss.

TheStreet Quant Rating: D (Sell)